Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update Nov 18, 2024
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 Nov 14, 2024
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer Nov 12, 2024
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 Nov 11, 2024
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 Nov 7, 2024
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia Aug 26, 2024
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq Aug 23, 2024
Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update Aug 13, 2024
Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 Aug 8, 2024
